Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving hundreds of leading biopharmaceutical companies globally:

AstraZeneca
Johnson and Johnson
Deloitte
Medtronic
Argus Health
Healthtrust
QuintilesIMS
Accenture
Boehringer Ingelheim

Generated: June 23, 2018

DrugPatentWatch Database Preview

TARKA Drug Profile

see a sample report or, see our see our flat-rate plans

« Back to Dashboard

When do Tarka patents expire, and when can generic versions of Tarka launch?

Tarka is a drug marketed by Abbvie and is included in one NDA.

The generic ingredient in TARKA is trandolapril; verapamil hydrochloride. There are ten drug master file entries for this compound. Four suppliers are listed for this compound. Additional details are available on the trandolapril; verapamil hydrochloride profile page.
Drug patent expirations by year for TARKA
Synonyms for TARKA
146994-90-3
1H-Indole-2-carboxylic acid, 1-((2S)-2-(((1S)-1-(ethoxycarbonyl)-3-phenylpropyl)amino)-1-oxopropyl)octahydro-, (2S,3aR,7aS)-, mixt. with alpha-(3-((2-(3,4-dimethoxyphenyl)ethyl)methylamino)propyl)-3,4-dimethoxy-alpha-(1-methy
C27H38N2O4.C24H34N2O5.Cl
LS-178657
SCHEMBL2526928
Trandolapril and Verapamil Hydrochloride
Trandolapril mixture with verapamil
Trandolapril mixture with verapamil HCl
Trandolapril mixture with verapamil hydrochloride
Trandolapril plus verapamil hydrochloride
Trandolapril-verapamil hydrochloride mixt.
TRANDOLAPRIL; VERAPAMIL HYDROCHLORIDE
Trandolapril/verapamil hydrochloride ER
Verapamil mixture with trandolapril

US Patents and Regulatory Information for TARKA

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Abbvie TARKA trandolapril; verapamil hydrochloride TABLET, EXTENDED RELEASE;ORAL 020591-003 Oct 22, 1996 AB RX Yes No ➤ Sign Up ➤ Sign Up ➤ Sign Up
Abbvie TARKA trandolapril; verapamil hydrochloride TABLET, EXTENDED RELEASE;ORAL 020591-002 Oct 22, 1996 AB RX Yes Yes ➤ Sign Up ➤ Sign Up ➤ Sign Up
Abbvie TARKA trandolapril; verapamil hydrochloride TABLET, EXTENDED RELEASE;ORAL 020591-001 Oct 22, 1996 AB RX Yes No ➤ Sign Up ➤ Sign Up ➤ Sign Up
Abbvie TARKA trandolapril; verapamil hydrochloride TABLET, EXTENDED RELEASE;ORAL 020591-004 Oct 22, 1996 AB RX Yes No ➤ Sign Up ➤ Sign Up ➤ Sign Up
Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

see a sample report or, see our see our flat-rate plans

Expired US Patents for TARKA

Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration
Abbvie TARKA trandolapril; verapamil hydrochloride TABLET, EXTENDED RELEASE;ORAL 020591-001 Oct 22, 1996 ➤ Sign Up ➤ Sign Up
Abbvie TARKA trandolapril; verapamil hydrochloride TABLET, EXTENDED RELEASE;ORAL 020591-004 Oct 22, 1996 ➤ Sign Up ➤ Sign Up
Abbvie TARKA trandolapril; verapamil hydrochloride TABLET, EXTENDED RELEASE;ORAL 020591-002 Oct 22, 1996 ➤ Sign Up ➤ Sign Up
Abbvie TARKA trandolapril; verapamil hydrochloride TABLET, EXTENDED RELEASE;ORAL 020591-003 Oct 22, 1996 ➤ Sign Up ➤ Sign Up
Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

Paragraph IV (Patent) Challenges for TARKA
Drugname Dosage Strength RLD Submissiondate
➤ Subscribe Extended-release Tablets 1 mg/240 mg ➤ Subscribe 2008-02-20
➤ Subscribe Extended-release Tablets 2 mg/180 mg and 2 mg/240 mg ➤ Subscribe 2007-11-09
➤ Subscribe Extended-release Tablets 4 mg/ 240 mg ➤ Subscribe 2007-07-24

see a sample report or, see our see our flat-rate plans

For more information try a trial or see the plans and pricing

Serving hundreds of leading biopharmaceutical companies globally:

Colorcon
McKesson
Julphar
Farmers Insurance
Merck
Daiichi Sankyo
US Army
Citi
Boehringer Ingelheim

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.